ACT 2: Cardiovascular outcome trials in diabetes

1. Which of the listed factors are important to modifying cardiovascular risk in T2DM?

2. Which statement is true? DPP-4 inhibitor CVOTs:

3. Which statement is true?

4. In EMPA-REG OUTCOME, empagliflozin significantly reduced three-point MACE by __%:

5. In EMPA-REG OUTCOME, empagliflozin significantly reduced cardiovascular death by __%:

6. In EMPA-REG OUTCOME, empagliflozin significantly reduced hospitalisation for HF by __%:

7. The CANVAS Program study of canagliflozin demonstrated a significant reduction in the primary three-point MACE endpoint, with each of the individual components demonstrating significant risk reduction.

8. Which statement is true? Canagliflozin:

9. Which of these best describes the study cohort of DECLARE-TIMI 58?

10. In comparing baseline characteristics of study cohorts, DECLARE-TIMI 58 differed from EMPA-REG OUTCOME and the CANVAS Program in that:

11. In DECLARE-TIMI 58, dapagliflozin demonstrated a significant 17% relative risk reduction for cardiovascular death and hospitalisation for HF.

12. Meta-analysis of pooled SGLT-2 inhibitor CVOT datasets indicates a significantly reduced risk of hospitalisation for HF and cardiovascular death in patients:

13. Real-world evidence from Scandinavian countries indicates that compared to DPP-4 inhibitors, dapagliflozin reduced risk for:

14. ADA/EASD guidance for the treatment of T2DM with inadequate glycaemic control and where ASCVD predominates recommends:

15. Which statement is false? ADA/EASD guidance for the treatment of T2DM with inadequate glycaemic control and without established ASCVD recommends: